Aurobindo Pharma Announces ₹800 Crore Share Buyback at ₹1,475/Share

Introduction to the Buyback Announcement

Aurobindo Pharma Limited's board of directors has approved a proposal to buy back equity shares worth up to ₹800 crores. The decision was made during a board meeting on April 6, 2026. The pharmaceutical company plans to repurchase the shares through a tender offer route, providing a structured exit opportunity for its shareholders at a premium price. This move signals the management's confidence in the company's financial health and its commitment to returning surplus cash to its investors.

Details of the Share Repurchase Program

The company will repurchase up to 54,23,728 fully paid-up equity shares, each with a face value of ₹1. The buyback price has been fixed at ₹1,475 per share. This repurchase represents 0.93% of the total paid-up equity share capital of the company. The total buyback size of ₹800 crores does not include transaction-related expenses such as brokerage fees, taxes, and other incidental costs. The tender offer mechanism ensures that all eligible shareholders, including promoters, can participate on a proportionate basis.

Key Buyback Parameters

To provide a clear overview, the essential details of the buyback offer are summarized below:

Financial Context and Strategic Rationale

The buyback size constitutes 3.93% of the company's aggregate paid-up equity share capital and free reserves based on standalone financial statements, and 2.62% based on consolidated financials as of March 31, 2025. Such corporate actions are often undertaken when a company's management believes its shares are undervalued in the market. By reducing the number of outstanding shares, a buyback can increase earnings per share (EPS) and improve return on equity, thereby enhancing shareholder value.

Governance and Regulatory Framework

A dedicated buyback committee has been established by the board to oversee the entire process and ensure compliance with all regulatory requirements. The buyback will be conducted in accordance with the SEBI (Buy-Back of Securities) Regulations, 2018, and the Companies Act, 2013. Under SEBI regulations, the company has the flexibility to increase the buyback price and decrease the number of shares to be repurchased until one working day before the record date, as long as the total buyback size of ₹800 crores remains unchanged.

Shareholding Pattern Overview

As of December 31, 2025, the promoter and promoter group held a majority stake in the company. The detailed shareholding structure provides insight into the key stakeholders who will be eligible to participate in the tender offer.

Market Reaction and Stock Performance

Following the announcement on April 6, 2026, the shares of Aurobindo Pharma experienced a slight decline. On the BSE, the stock fell by 1.26% to a low of ₹1,319. Despite this short-term reaction, the stock has shown strong performance over the medium term, gaining 21% in the last six months. The buyback price of ₹1,475 per share represents a significant premium over the closing price preceding the announcement, making the offer attractive for eligible shareholders.

Comparison with Past Corporate Actions

This is not the first time Aurobindo Pharma has opted to return capital to its shareholders via a buyback. The company conducted a similar exercise in August 2024, when it repurchased 51.36 lakh equity shares at ₹1,460 per share, with a total outlay of ₹750 crores. Consistent buybacks can be interpreted as a positive signal about the company's long-term growth prospects and stable cash flow generation.

Other Corporate Updates

In a separate filing, Aurobindo Pharma also informed the stock exchanges about an extension to its timeline for acquiring a stake in Swarnaakshu Solar Power Private Limited. The company now expects to complete the acquisition of up to a 26% stake on or before June 30, 2026. The delay is attributed to pending approvals from the state government for setting up a captive solar power plant.

Conclusion

Aurobindo Pharma's ₹800 crore share buyback is a significant corporate action aimed at optimizing its capital structure and rewarding shareholders. The premium price of ₹1,475 per share through a tender offer provides a valuable opportunity for investors. Shareholders who hold the stock as of the record date of April 17, 2026, will be eligible to participate. The company is expected to release a public announcement and a letter of offer with detailed timelines and procedures in due course.